Since iFSP1, the only currently available FSP1 inhibitor, cannot be used in animal treatment, we hope that our study can motivate the future development of potent FSP1 inhibitors suitable for in vivo treatment and further testing of such inhibitors as radiosensitizers in treating KEAP1 mutant lung cancers. Here, AIFM2 is linked to lung cancer.